apadenoson
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
4
Phase 4
0
Earliest trial started Apr 1, 2005 (NCT00162084)
Timeline
Indications
Mechanism of action
- Adenosine A2a receptorAGONIST
ADORA2A agonist
All registered studies Discontinued Developed as pharmacologic stress agent for myocardial perfusion imaging.
Chemistry & pharmacology
Loading structure…
SMILES
CCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)nc(C#CC[C@H]4CC[C@H](C(=O)OC)CC4)nc32)[C@H](O)[C@@H]1O- Mol. weight
- 486.53 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1950649 ↗
Also known as
- apadenoson
- apadenoson
- apadenoson
- apadenoson
- bms-068645
- bms-068645
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01313572 | Phase 3 | Aug 1, 2011 | Forest Laboratories, PPD |
| NCT00990327 | Phase 3 | Nov 1, 2009 | Forest Laboratories, PPD |
| NCT00380198 | Phase 3 | Jul 1, 2006 | Bristol-Myers Squibb, Forest Laboratories |
| NCT00162071 | Phase 2 | Jul 1, 2005 | Forest Laboratories, St. Luke's-Roosevelt Hospital Center |
| NCT00162084 | Phase 3 | Apr 1, 2005 | Bristol-Myers Squibb, Forest Laboratories |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Forest Laboratories | For profit | 5 | 5 | 2 | 2005 |
| Bristol-Myers Squibb | For profit | 2 | 0 | 1 | 2005 |
| PPD | For profit | 2 | 0 | 1 | 2009 |
| St. Luke's-Roosevelt Hospital Center | Academic/Hospital | 1 | 0 | 1 | 2005 |
4 organizations
Page 1 / 1